Results

For the primary safety measure of life-threatening bleeding complications during the initial 36 hours post-treatment, the overall mortality rate was lower, although statistically insignficant, in the IMS study group (13/80; 16%) when compared to the NINDS tPA group (39/182; 21%; p=0.33). Rates of intracerebral hemorrhage were similar among treatment groups in both trials. There was also no difference between the IMS study group and the NINDS tPA group in the secondary outcome measures of Rankin, NIHSS, Barthel, and Glasgow scores at 90 days.